The Vascular Dementia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vascular Dementia: An Overview
According to the Alzheimer’s Association, Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various regions of the brain, depriving them of oxygen and nutrients. Inadequate blood flow can damage and eventually kill cells anywhere in the body, but the brain is especially vulnerable.
Currently, there are no FDA-approved therapies for the treatment of vascular dementia. Pharmacological treatment primarily works to prevent the worsening of vascular dementia by treating the underlying disease, such as hypertension, hyperlipidemia, or diabetes mellitus.
Vascular Dementia Market Key Facts
-
According to a study titled “Vascular dementia: diagnosis, treatment and medical management” , (2019), in the UK, an estimated 954,000 people have dementia, 162,197 have vascular dementia (VaD). Some 95,410 have mixed dementia, which is a mixture of vascular dementia and Alzheimer’s disease.
-
Vascular dementia is generally considered the second most common subtype of dementia, after Alzheimer’s disease, accounting for roughly 15% to 20% of dementia cases in North America and Europe. Also, the age-specific risk of all-cause dementia in the United States and Europe has declined by about 20% per decade since the late 20th century, [Wolters J. F. et. al. 2019]
-
According to a study by Podcasy J. L. et al, (2016), males are at greater risk of developing vascular dementia.
The Vascular Dementia market size is expected to increase during the forecast period owing to the expected launch of therapies, increase in government initiatives, and extensive research and development activities of pharmaceutical companies.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Vascular Dementia market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Vascular Dementia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Vascular Dementia Epidemiology
The epidemiology section covers insights into the historical and current Vascular Dementia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.
Vascular Dementia Epidemiology Segmentation
-
Prevalent Cases of Dementia
-
Gender-Specific Prevalent Cases of Vascular Dementia
-
Diagnosed and Treatable Cases of Vascular Dementia
-
Age-Specific Prevalent Cases of Vascular Dementia
-
Prevalent Cases of Vascular Dementia
Vascular Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vascular Dementia market or expected to get launched during the study period. The analysis covers Vascular Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vascular Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/vascular-dementia-market
Vascular Dementia Therapeutics Analysis
The available therapeutics treatment options in the Vascular Dementia landscape focus on improving patients’ quality of life and reducing disease progression.
The emerging drugs landscape does not represent a particularly promising picture due to the lack of late-stage clinical products, which is quite evidently based on the scarcity of clinical trials being conducted. There are few therapies that are being developed for VaD by the pharma companies in the domain. The expected launch of emerging therapies will create a significant impact on the market size during the forecast period.
Some of the key companies in the Vascular Dementia Market include:
-
Otsuka
-
Lundbeck
-
Eisai
And others.
Vascular Dementia Therapies covered in the report include:
-
Brexpiprazole
-
E2027
And many others.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/vascular-dementia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Vascular Dementia Competitive Intelligence Analysis
4. Vascular Dementia Market Overview at a Glance
5. Vascular Dementia Disease Background and Overview
6. Vascular Dementia Patient Journey
7. Vascular Dementia Epidemiology and Patient Population
8. Vascular Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Vascular Dementia Unmet Needs
10. Key Endpoints of Vascular Dementia Treatment
11. Vascular Dementia Marketed Products
12. Vascular Dementia Emerging Therapies
13. Vascular Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Vascular Dementia Market Outlook (7 major markets)
16. Vascular Dementia Access and Reimbursement Overview
17. KOL Views on the Vascular Dementia Market.
18. Vascular Dementia Market Drivers
19. Vascular Dementia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/vascular-dementia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Latest Reports By DelveInsight
DelveInsight’s “Paraganglioma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Paraganglioma market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/